ADMA equity (ADMA)

Key Updates

ADMA declined 3.76% to $7.93 since the May 23 report, as Pomerantz Law Firm issued another investor alert on May 28, reinforcing the securities fraud investigation narrative. The stock has now fallen 56.52% year-to-date and 58.65% over six months, with the current price representing a 30% decline from the initial March 24 short report level of $11.33. The persistent stream of law firm announcements—now from both Pomerantz and Rosen—continues to pressure the stock despite no new material developments in the underlying allegations. The May 28 alert reiterates the same three core events: the March 24 Culper Research allegations, the March 26 Cantor Fitzgerald downgrade, and the May 6 guidance withdrawal.

Current Trend

ADMA remains in a severe downtrend with the stock down 56.52% YTD, trading at $7.93. The price has established a new lower support level around $7.90-$8.00, breaking below the previous $8.20-$8.50 range identified in prior reports. The stock has declined in 4 of the last 5 trading periods analyzed, with only a brief 2.62% bounce on May 19 interrupting the descent. The 1-month decline of 27.25% and 5-day decline of 7.36% demonstrate accelerating downward momentum. Resistance now sits at $8.50-$8.70, with critical resistance at the $11.00-$11.50 pre-crisis level. The stock is trading at approximately 70% below its pre-allegation price, reflecting severe market skepticism about the company's business practices and future prospects.

Investment Thesis

The investment thesis for ADMA has deteriorated to a speculative recovery play contingent on the company successfully refuting channel stuffing allegations and restoring credibility with investors and analysts. The core issues remain: (1) Culper Research's allegations that 2025's reported 20% revenue growth was artificially inflated through undisclosed related-party distributor channel stuffing, with actual revenues declining 3%; (2) management's perceived inadequate response to these allegations, prompting a Cantor Fitzgerald downgrade; and (3) the May 6 withdrawal of long-term financial guidance citing competitive market dynamics in U.S. plasma products and immunoglobulin markets. The ongoing securities fraud investigations by multiple law firms add legal risk and reputational damage. Any investment case now depends on ADMA providing transparent evidence of legitimate revenue growth, resolving legal challenges favorably, and demonstrating sustainable competitive positioning in an increasingly challenging market environment.

Thesis Status

The investment thesis remains severely impaired with no material improvement since the May 23 report. The May 28 Pomerantz alert introduces no new information but reinforces the legal risk profile by maintaining public attention on the fraud allegations. The absence of any company rebuttal, clarification, or positive developments over the past week suggests management either lacks compelling counterarguments or is constrained by legal counsel. The 3.76% decline since the last report indicates continued selling pressure despite the stock already being down over 56% YTD. The thesis deterioration is complete: from a growth story (20% revenue growth) to alleged accounting manipulation to guidance withdrawal to securities litigation. Without a credible company response or third-party validation of revenue quality, the stock remains uninvestable at current information levels.

Key Drivers

The dominant driver remains the legal and reputational fallout from the March 24 Culper Research short report. Pomerantz Law Firm's May 28 investor alert perpetuates the narrative that ADMA engaged in channel stuffing with an undisclosed related-party distributor, artificially inflating 2025 revenue growth to 20% while actual revenues declined 3%. The alert details three sequential stock collapses: the initial 16.63% decline to $11.33 on March 24, the additional 13.91% drop to $8.29 on March 26 following the Cantor Fitzgerald downgrade, and the 15.97% decline to $8.47 on May 7 after guidance withdrawal. The cumulative impact of these events has destroyed investor confidence. The competitive dynamics in U.S. plasma products and immunoglobulin markets cited in the guidance withdrawal suggest fundamental business headwinds beyond the accounting allegations. The ongoing investigations by both Pomerantz and Rosen law firms create overhang risk of class action settlements and further reputational damage.

Technical Analysis

ADMA is in capitulation territory, trading at $7.93 after declining 56.52% YTD and 58.65% over six months. The stock broke below the $8.20 support level identified in previous reports and is testing new lows around $7.90. The 5-day decline of 7.36% and 1-month decline of 27.25% indicate persistent selling pressure with no signs of stabilization. Volume characteristics suggest continued distribution rather than accumulation. Immediate resistance sits at $8.50 (recent breakdown level), with stronger resistance at $8.70-$9.00 and critical resistance at $11.00-$11.50 (pre-crisis levels). Support is minimal, with psychological support at $7.50 and $7.00. The price action shows no bullish divergences or reversal patterns. The technical picture reflects complete loss of investor confidence, with each bounce met by renewed selling. Any recovery would require reclaiming $8.50 on sustained volume to suggest a potential bottoming process.

Bull Case

• Potential for company to provide definitive evidence refuting channel stuffing allegations, including transparent disclosure of distributor relationships and inventory levels, which could trigger significant short covering given the 58.65% decline from six-month highs. Source
• Valuation compression to $7.93 (down 56.52% YTD) may present contrarian opportunity if investigations conclude without material findings or if company settles litigation quickly, removing legal overhang. Source
• Technical oversold conditions with stock down 27.25% in one month could attract value-oriented buyers if company provides any positive catalyst or business update. Source
• Underlying plasma products business may retain value if revenue quality issues prove less severe than alleged, with U.S. immunoglobulin market fundamentals potentially supporting legitimate growth. Source
• Potential acquisition target at distressed valuation if core business assets remain viable, with strategic buyers potentially seeing value in plasma collection infrastructure despite accounting controversies. Source

Bear Case

• Culper Research allegations that ADMA's reported 20% revenue growth in 2025 was driven by channel stuffing with undisclosed related-party distributor, with actual revenues declining 3%, represent fundamental fraud risk that could result in restatements, regulatory action, and criminal liability. Source
• May 6 withdrawal of long-term financial guidance citing "competitive market dynamics in U.S. plasma products and immunoglobulin markets" indicates fundamental business deterioration beyond accounting issues, with 15.97% stock decline to $8.47 on May 7 reflecting market's loss of confidence in business model. Source
• Multiple securities fraud investigations by Pomerantz and Rosen law firms create significant legal liability risk, with potential class action settlements and ongoing reputational damage deterring institutional investors. Source
• Cantor Fitzgerald downgrade on March 26 citing inadequate company response to allegations demonstrates analyst community skepticism, with subsequent 13.91% decline to $8.29 reflecting institutional selling pressure. Source
• Cumulative 56.52% YTD decline and persistent selling pressure with no management rebuttal or clarification suggests either inability to refute allegations or legal constraints preventing disclosure, both indicating severe fundamental impairment. Source